Faron Pharmaceuticals Oy (GB:FARN) has released an update.
Faron Pharmaceuticals Oy, a clinical-stage biopharmaceutical company, has granted 645,000 options to directors and staff under its 2019 Share Option Plan, exercisable between 2025 and 2029. These options could potentially increase the company’s share capital by 0.61% if fully exercised. The grants are part of Faron’s strategy to incentivize and retain key personnel as it advances its lead immunotherapy drug, bexmarilimab, through clinical trials for treating hematological cancers.
For further insights into GB:FARN stock, check out TipRanks’ Stock Analysis page.
